Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05079321
Other study ID # 40887
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 29, 2021
Est. completion date August 28, 2023

Study information

Verified date November 2023
Source University of Waterloo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of scleral contact lens wear on a DE population using coated (Hydra-PEG) and uncoated (control) lenses. Symptoms of DE, quality of the tear film, quality of life, epithelial and overall corneal thickness, vision and comfort will be assessed before and after dispensing and wearing the lenses for four weeks.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date August 28, 2023
Est. primary completion date August 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: A person is eligible for inclusion in the study if he/she: - Is at least 18 years of age and has full legal capacity to volunteer. - Has read, understood, and signed the information consent letter. - Has been diagnosed with dry eyes. - Has reduced tear break up time (NITBUT) and/or reduced tear meniscus height (TMH), clinical sign of dry eye disease and contact lens discomfort or is symptomatic of dry eye. - Is willing and able to follow instructions and maintain the appointment schedule. - Has greater than 13 points on the OSDI. - Has greater than 4 points on the Standardized Patient Evaluation of Eye Dryness (SPEED). Exclusion Criteria: A person will be excluded from the study if he/she: - Is using any topical medications that will likely affect the study outcome. - Has undergone any form of corneal surgery. - Has any known allergies or sensitivity to the diagnostic pharmaceuticals or products, such as fluorescein, used in this study. - Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye not related to the signs of dry eye. - Has any clinically significant lid or conjunctival abnormalities and active neovascularization on the cornea. - Anatomic variations of the conjunctiva that can impair proper scleral or soft contact lens wear/fitting - Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration) which may significantly impact visual function and assessment. - Is participating in any other type of eye related clinical or research study. - Has any active ocular infection and may require topical medications. - Currently taking any systemic medication that may affect the study outcome. - Is pregnant - Has been diagnosed, recovered, or tested positive but asymptomatic with COVID-19.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Hydra-PEG
Zen™ RC scleral lenses (Hydra-PEG coated)
Uncoated
Zen™ RC scleral lenses (non-coated)

Locations

Country Name City State
Canada School of Optometry & Vision Science, University of Waterloo Waterloo Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Waterloo

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Corneal Thickness Mean corneal thickness as measured with Pentacam HR and Spectralis OCT (µm) At screening
Primary Mean Corneal Thickness Mean corneal thickness as measured with Pentacam HR and Spectralis OCT (µm) Immediately after dispense of coated lens
Primary Mean Corneal Thickness Mean corneal thickness as measured with Pentacam HR and Spectralis OCT (µm) Immediately after dispense of uncoated lens
Primary Mean Corneal Thickness Mean corneal thickness as measured with Pentacam HR and Spectralis OCT (µm) After 4 weeks wear of coated lens
Primary Mean Corneal Thickness Mean corneal thickness as measured with Pentacam HR and Spectralis OCT (µm) After 4 weeks wear of uncoated lens
Primary Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score he CLDEQ-8 is a validated questionnaire used to quantify symptoms experienced by the contact lenses (CLs) wearer. The participants were asked to respond to 8 questions about how their CLs performed over the preceding 2-week period. 4 questions (Eye discomfort, Eye dryness, Changeable blurry vision and Closing your eyes) answered on a scale of 0=Never to 4=Constantly; 3 questions about the end of wearing time (Discomfort, Dryness, Changeable blurry vision) answered on a scale of 0=Never have it to 5=Very Intense and 1 question (Removing your lenses) on a scale of 1=Never to 6=Several times a day for a total possible score of 1(best) to 37 (worst). After 2 weeks of wear of coated lens
Primary Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score he CLDEQ-8 is a validated questionnaire used to quantify symptoms experienced by the contact lenses (CLs) wearer. The participants were asked to respond to 8 questions about how their CLs performed over the preceding 2-week period. 4 questions (Eye discomfort, Eye dryness, Changeable blurry vision and Closing your eyes) answered on a scale of 0=Never to 4=Constantly; 3 questions about the end of wearing time (Discomfort, Dryness, Changeable blurry vision) answered on a scale of 0=Never have it to 5=Very Intense and 1 question (Removing your lenses) on a scale of 1=Never to 6=Several times a day for a total possible score of 1(best) to 37 (worst). After 2 weeks of wear of uncoated lens
Primary Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score he CLDEQ-8 is a validated questionnaire used to quantify symptoms experienced by the contact lenses (CLs) wearer. The participants were asked to respond to 8 questions about how their CLs performed over the preceding 2-week period. 4 questions (Eye discomfort, Eye dryness, Changeable blurry vision and Closing your eyes) answered on a scale of 0=Never to 4=Constantly; 3 questions about the end of wearing time (Discomfort, Dryness, Changeable blurry vision) answered on a scale of 0=Never have it to 5=Very Intense and 1 question (Removing your lenses) on a scale of 1=Never to 6=Several times a day for a total possible score of 1(best) to 37 (worst). After 4 weeks of wear of coated lens
Primary Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score he CLDEQ-8 is a validated questionnaire used to quantify symptoms experienced by the contact lenses (CLs) wearer. The participants were asked to respond to 8 questions about how their CLs performed over the preceding 2-week period. 4 questions (Eye discomfort, Eye dryness, Changeable blurry vision and Closing your eyes) answered on a scale of 0=Never to 4=Constantly; 3 questions about the end of wearing time (Discomfort, Dryness, Changeable blurry vision) answered on a scale of 0=Never have it to 5=Very Intense and 1 question (Removing your lenses) on a scale of 1=Never to 6=Several times a day for a total possible score of 1(best) to 37 (worst). After 4 weeks of wear of uncoated lens
Primary Tear film osmolarity Tear film osmolarity measures with a Tearlab Osmolarity System At screening
Primary Tear film osmolarity Tear film osmolarity measures with a Tearlab Osmolarity System After 4 weeks of wear of uncoated lens
Primary Tear film osmolarity Tear film osmolarity measures with a Tearlab Osmolarity System After 4 weeks of wear of coated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 1 week of wear of uncoated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 1 week of wear of coated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 2 weeks of wear of uncoated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 2 weeks of wear of coated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 3 weeks of wear of uncoated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 3 weeks of wear of coated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 4 weeks of wear of uncoated lens
Primary Contact Lens Impact on Quality of Life (CLIQ) questionnaire score The 28-item CLIQ questionnaire contains five responses (none = score 1; little = score 2; moderate = score 3; extreme = score 4 and unable = score 5). After 4 weeks of wear of coated lens
Primary Inflammatory marker level in tear film Level of MMP-9, as measured by InflammaDry At screening
Primary Inflammatory marker level in tear film Level of MMP-9, as measured by InflammaDry After 4 weeks of wear of coated lens
Primary Inflammatory marker level in tear film Level of MMP-9, as measured by InflammaDry After 4 weeks of wear of uncoated lens
See also
  Status Clinical Trial Phase
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A